Integer (NYSE:ITGR) Releases FY 2025 Earnings Guidance

Integer (NYSE:ITGR) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 5.840-6.200 for the period, compared to the consensus estimate of 6.070. The company issued revenue guidance of $1.8 billion-$1.9 billion, compared to the consensus revenue estimate of $1.8 billion.

Integer Stock Down 3.9 %

NYSE:ITGR traded down $5.26 on Friday, hitting $129.96. 499,343 shares of the company’s stock were exchanged, compared to its average volume of 265,046. The firm has a 50-day moving average price of $137.92 and a 200-day moving average price of $132.31. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.95 and a quick ratio of 2.09. Integer has a 52 week low of $98.63 and a 52 week high of $146.36. The company has a market cap of $4.36 billion, a P/E ratio of 38.68, a price-to-earnings-growth ratio of 1.72 and a beta of 1.13.

Integer (NYSE:ITGR) last issued its quarterly earnings results on Thursday, February 20th. The medical equipment provider reported $1.43 EPS for the quarter, missing the consensus estimate of $1.46 by ($0.03). Integer had a return on equity of 11.65% and a net margin of 6.92%. The business had revenue of $449.50 million for the quarter, compared to the consensus estimate of $446.28 million. As a group, analysts expect that Integer will post 6.01 EPS for the current fiscal year.

Analysts Set New Price Targets

ITGR has been the topic of a number of research analyst reports. Citigroup upped their target price on shares of Integer from $130.00 to $145.00 and gave the company a “neutral” rating in a report on Wednesday, December 11th. Piper Sandler reaffirmed an “overweight” rating and issued a $140.00 target price (up from $125.00) on shares of Integer in a report on Friday, October 25th. Wells Fargo & Company reaffirmed an “overweight” rating and issued a $160.00 target price on shares of Integer in a report on Tuesday, December 3rd. Oppenheimer cut shares of Integer from an “outperform” rating to a “market perform” rating in a report on Friday. Finally, KeyCorp upped their target price on shares of Integer from $144.00 to $154.00 and gave the company an “overweight” rating in a report on Friday, January 24th. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $147.67.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.